Immunovant's proof-of-concept study for IMVT-1402 in cutaneous lupus erythematosus (CLE) failed to achieve statistical significance on its primary endpoint. While positive trends were observed, the company has decided to discontinue development of IMVT-1402 for CLE, indicating a setback for this specific drug candidate and its potential market.
Immunovant announced that its IMVT-1402 trial for cutaneous lupus erythematosus (CLE) did not meet its primary endpoint, leading to the discontinuation of development for this indication. This is a significant negative catalyst for Immunovant as it removes a potential revenue stream and highlights a failure in its drug pipeline for CLE. While the drug showed a favorable safety profile and positive trends, the lack of statistical significance on the primary endpoint was a dealbreaker for the company's internal development bar. This news will likely lead to a short-term negative reaction in IMVT's stock price, and potentially ROIV's, as investors reassess the company's pipeline strength and future growth prospects, though other development timelines remain on track.